Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma

Suto, T; Fukuda, Shinsaku; Moriya, Noriko; Watanabe, Yasuhiro; Sasaki, Daisuke; Yoshida, Yutaka; Sakata, Y.

doi:10.1007/bf00686688

Cited by 26 publications

(15 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, various BRMs such as natural products involving oriental medicines, cytokines, synthetic adjuvants having biological activity to enhance host defense system have been applied to cancer immunotherapy (Suto et al, 1994;Schmeda-Hirschmann et al, 2001;Kang et al, 2002;Saiki, 2000). In many cases, BRMs activate immune-related cells such as NK cells, lymphokine-activated killer (LAK) cells and macrophages to control the growth of the cancer and its metastasis (Yoon et al, 1998;Sakamaki et al, 1992;Habu et al, 1981).…”

Section: Discussionmentioning

confidence: 94%

“…Biological response modifier (BRM) has been thought to be a useful tool to suppress tumor growth and inhibit tumor metastasis (Suto et al, 1994;Yoo et al, 1994). In fact, various BRMs such as natural products involving oriental medicines, cytokines, synthetic adjuvants having biological activity to enhance host defense system have been applied to cancer immunotherapy (Suto et al, 1994;Schmeda-Hirschmann et al, 2001;Kang et al, 2002;Saiki, 2000).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Anti-metastatic activity of Acanthopanax senticosus extract and its possible immunological mechanism of action

Yoon

Yoo

Lee

et al. 2004

Journal of Ethnopharmacology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Anti-metastatic activity of Acanthopanax senticosus extract and its possible immunological mechanism of action

Yoon

Yoo

Lee

et al. 2004

Journal of Ethnopharmacology

View full text Add to dashboard Cite

“…Biological response modifiers have previously been used as a tool for inhibiting tumour growth and metastasis (33,34). In the tumour microenvironment, tumour cells often secrete immunosuppressive factors that alter host immune function and suppress immune response cells (35).…”

Section: Discussionmentioning

confidence: 99%

Anti‑tumour effects of polysaccharide extracted from Acanthopanaxï¿½senticosus and cell‑mediated immunity

Meng

Pan²,

Liu

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

Abstract. Acanthopanax senticosus, also known as Siberian ginseng, is widely distributed throughout northern Asia and used in traditional Chinese medicine; it has been reported to prevent a number of diseases. However, the association between the antitumour and immunostimulatory activities of polysaccharide extracted from A. senticosus (ASPS) remains to be elucidated. The aim of the present study was to investigate the anti-tumour and immunomodulatory effects of polysaccharide extracted from ASPS on Crocker sarcoma S 180 , hepatic carcinoma H 22 and uterine cervical carcinoma U 14 tumour cell lines implanted in mice. High performance liquid chromatography, gas chromatography and infrared spectroscopy were used to analyse the monosaccharide composition of ASPS. The monosaccharide composition of ASPS (Arabic candy: Xylose: Glucose: Mannose) was 7.1:22.3:7.6:1.0. On day 0, female Kunming mice, were injected subcutaneously with 1x10 8 tumour cells in 0.2 ml. The inoculated mice were subsequently divided into five groups (10 mice/group) as follows: Model group, treated with normal saline; positive control group, treated with 30 mg/kg cyclophosphamide (CTX); and three treatment groups, treated with 200, 100 or 50 mg/kg ASPS. Non-inoculated mice were divided into the normal group, which was treated with normal saline, and the negative control group, which was treated with 200 mg/kg ASPS (n=10/group). CTX and ASPS were administered intragastrically once daily for 10 days. All mice were sacrificed on day 11. ASPS was observed to have an inhibitory effect on the growth of S 180 , H 22 and U 14 cells in solid and ascites tumour-bearing mice. Serum interleukin (IL)-2 and IL-12 levels were significantly increased in S 180 solid tumour-bearing mice treated with 200 or 100 mg/kg ASPS compared with mice in the normal, control and model groups (P<0.05), whereas serum IL-2 and IL-12 levels were significantly decreased in the cyclophosphamide treatment group compared with the normal, control and model groups (P<0.05). No significant difference in serum levels of tumour necrosis factor-α level was observed between any groups. In S 180 and U 14 solid tumour-bearing mice, no significant differences in serum levels of interferon (INF)-γ level in were observed between groups; however, in H 22 solid tumour-bearing mice, treatment with ASPS significantly increased serum INF-γ compared with the positive control group (P<0.05). The results may provide a basis for the potential application of ASPS in clinical treatment for cancer.

show abstract

“…Several types of immunotherapy including lymphokine-activated killer (LAK) cell injections have been used for HCC treatment. However, no satisfactory results were obtained (5)(6)(7)(8), as HCC is generally considered a very non-immunogenic cancer.…”

Section: Introductionmentioning

confidence: 99%

CD80 transfected human hepatocellular carcinoma cells activate cytotoxic T lymphocytes to target HCC cells with shared tumor antigens

Chan

Xie²

2004

Oncol Rep

View full text Add to dashboard Cite

Abstract. Human HCC cell lines (BEL-7402, SMMC-7721 and QGY-7703) do not express CD80 molecules, although they express MHC class I molecules and ICAM-1. HCC's poor immunogenicity may therefore be due to lack of CD80 molecules. This study first investigated whether CD80 molecules could provide minimal co-stimulatory signal for establishing an efficient anti-tumor immunity in HCC and second, whether the transfection of CD80 into the BEL-7402 cell line could induce T cell activation for targeting other HCC cell lines expressing shared common antigens. The transfection of cDNA encoding CD80 into ICAM-1 + HCC BEL-7402 cells was confirmed by flow cytometrical analysis. The CD80-tranfected cells could enhance the immunogenicity of BEL-7402 cells as detected by T cell proliferation assay, and also activated the T cells at a higher proliferation rate comparing with the BEL-7402 cells transfected with vector only. The CD80-transfected cell line was also found able to activate T cells which subsequently induced cell lysis of SMMC-7721, QGY-7703 and parent BEL-7402 cell lines as detected by cytotoxicity assay. It can be concluded that the cytotoxicity was due to MHC class I restricted CD8 + cytotoxic T lymphocytes, but not natural killer (NK) cells, since this cytotoxic effect could be blocked by anti-MHC class I antibody and the cytotoxicity was shown very low in NKcell-sensitive K562 cell line. Electroporation of CD80 cDNA into human HCC cells could increase the expression of the functional CD80 molecules and enhance the immunogenicity of the genetically-modified HCC cells to activate T cells for targeting 3 HCC cell lines in an HLA-restricted manner.

show abstract

Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma

Cited by 26 publications

References 4 publications

Anti-metastatic activity of Acanthopanax senticosus extract and its possible immunological mechanism of action

Anti-metastatic activity of Acanthopanax senticosus extract and its possible immunological mechanism of action

Anti‑tumour effects of polysaccharide extracted from Acanthopanaxï¿½senticosus and cell‑mediated immunity

CD80 transfected human hepatocellular carcinoma cells activate cytotoxic T lymphocytes to target HCC cells with shared tumor antigens

Contact Info

Product

Resources

About